SILVERARC CAPITAL MANAGEMENT, LLC
Position in ELVN — Enliven Therapeutics, Inc.
CIK 1816307
BOSTON, MA
Position in ELVN
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$24,836,136
+$24,617,619 QoQ
Shares Held
489,382
+4484.4% QoQ
Ownership
0.668%
of shares outstanding
% of Portfolio
2.76%
of 13F equity value
Holder Rank
#35
of 210 holders
Holding Since
Jun 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ELVN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026SILVERARC CAPITAL MANAGEMENT, LLC holds $802,586,993 across 53 Biotechnology names. ELVN ranks #11 (3.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ASND |
Ascendis Pharma A/S
|
206,234 | $55,006,732 | |
| 2 | CELC |
Celcuity Inc.
|
500,996 | $52,414,201 | |
| 3 | COGT |
Cogent Biosciences, Inc.
|
1,280,707 | $49,563,360 | |
| 4 | URGN |
UroGen Pharma Ltd.
|
1,301,979 | $47,912,827 | |
| 5 | IMNM |
Immunome Inc.
|
2,017,009 | $42,740,420 | |
| 6 | DNTH |
Dianthus Therapeutics, Inc. /DE/
|
390,000 | $38,017,200 | |
| 7 | RYTM |
Rhythm Pharmaceuticals, Inc.
|
311,461 | $34,581,514 | |
| 8 | ORKA |
Oruka Therapeutics, Inc.
|
352,802 | $33,576,166 |
All Filings in ELVN
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $24,836,136 | 489,382 | Shares | Sole | 2026-08-13 | |
| 2025-09-30 | $218,517 | 10,675 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $200,600 | 10,000 | Shares | Sole | 2025-08-14 | |
| No filing history on record for this holder in this stock. | ||||||